G Protein News and Research

RSS

International team identifies key protein in development of drug-resistant leukemia

Now an international team led by researchers at the University of California, San Francisco and joined by scientists of the Freiburg excellence cluster BIOSS - Centre for Biological Signalling Studies, has identified a protein called BCL6 which plays a key role in the development of drug-resistance in leukemia.

20 May 2011

AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.

20 May 2011

GIS discovery could help generate stem cells more efficiently for biomedical applications

A team of scientists from Genome Institute of Singapore (GIS) of the Agency for Science, Technology and Research (A*STAR) have shown how proteins involved in controlling genes work together to carry out their functions in stem cells and demonstrated for the very first time, how they can change interaction partners to make other types of cells.

20 May 2011

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

Naltrexone reduced inflammation in Crohn's patients in a research study at Penn State College of Medicine.

20 May 2011

CSL-Behring recombinant factor research presented

Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at an international medical congress on May 22, 2011. CSL Behring is a global biotherapeutics company specializing in plasma-derived and recombinant therapies and is a subsidiary of CSL Limited (ASX:CSL).

19 May 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen Corporation announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy.

19 May 2011

Sensitive troponin assays improve clinical outcome and cardiac patient management

Research presented this week at the International Federation of Clinical Chemistry Congress and Laboratory Medicine showed that using a lower diagnostic threshold for troponin improves clinical outcomes and patient survival in patients with suspected acute coronary syndromes.

19 May 2011

TissueGene commences enrollment in TG-C Phase II trial for severe knee osteoarthritis

TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.

19 May 2011

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.

19 May 2011

Scientists identify key protein behind drug-resistant leukemia

Acute lymphoblastic leukemia, or ALL, is the most common form of childhood cancer. While most children treated for this disease survive, in a subgroup of patients the disease does not respond to treatment.

19 May 2011

Two genes linked to worst cases of esophageal cancer

University of Rochester Medical Center researchers have pinpointed two genes that are amplified in the worst cases of esophageal cancer, providing data to support a new investigational treatment that targets those same genes.

19 May 2011

MDC researchers comprehensively quantify gene expression for the first time

How do genes control us? This fundamental question of life still remains elusive despite decades of research. Genes are blueprints for proteins, but it is the proteins that actually carry out vital functions in the body for maintaining life. Diseases such as cancer are not only characterized by altered genes, but also by disturbed protein production.

19 May 2011

New breast cancer biomarker may help identify women's response to tamoxifen

Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy.

19 May 2011

Estradiol may exacerbate tumor growth in breast cancer

A recently discovered enzyme drives the production of a potent form of estrogen in human breast cancer tissue, researchers from the University of Illinois at Chicago College of Medicine have found.

19 May 2011

'Gatekeeper' protein plays a key role in skin-cancer prevention

New research from North Carolina State University shows that a "gatekeeper" protein plays an important role in skin-cancer prevention in humans and lab mice.

19 May 2011

Fragile X syndrome may be treatable

Advancements over the last 10 years in understanding intellectual disability (ID, formerly mental retardation), have led to the once-unimaginable possibility that ID may be treatable, a review of more than 100 studies on the topic has concluded. It appears in ACS Chemical Neuroscience.

18 May 2011

Serpin-2 molecule may be a perfect target for preventing mosquito's immunity

Mosquitoes are becoming more resistant to current pesticides. That's troubling to Kansas State University biologist Kristin Michel, as it means malaria and other mosquito-borne diseases will continue spreading. A recent grant from the National Institutes of Health may change all that.

18 May 2011

Aeterna Zentaris first quarter revenues increase to $7.4 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the first quarter ended March 31, 2011.

18 May 2011

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time.

18 May 2011

Novel gene associated with heart development and aging process

Researchers at the University of Ottawa Heart Institute (UOHI) have identified a novel gene in the nucleus of muscle and brain cells that affects heart development and the aging process. Their investigation brings the promise of new treatments for an old, failing heart.

18 May 2011

G Protein News and Research

International team identifies key protein in development of drug-resistant leukemia

AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency

GIS discovery could help generate stem cells more efficiently for biomedical applications

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

CSL-Behring recombinant factor research presented

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Sensitive troponin assays improve clinical outcome and cardiac patient management

TissueGene commences enrollment in TG-C Phase II trial for severe knee osteoarthritis

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Scientists identify key protein behind drug-resistant leukemia

Two genes linked to worst cases of esophageal cancer

MDC researchers comprehensively quantify gene expression for the first time

New breast cancer biomarker may help identify women's response to tamoxifen

Estradiol may exacerbate tumor growth in breast cancer

'Gatekeeper' protein plays a key role in skin-cancer prevention

Fragile X syndrome may be treatable

Serpin-2 molecule may be a perfect target for preventing mosquito's immunity

Aeterna Zentaris first quarter revenues increase to $7.4 million

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Novel gene associated with heart development and aging process

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News